Skip navigation

Bayer Q1 net up 8.4 percent, raises outlook

Chemical and drug company Bayer AG said Thursday that net profit rose 8.4 percent to €684 million ($1.0 billion) in the first quarter, thanks to rising demand from farmers for chemicals and seeds and from the auto and construction industries for high-tech materials. Full story

New studies point to clot risk of Bayer's Yasmin

New evidence emerged on Friday that women taking Bayer's best-selling contraceptive Yasmin may run a higher risk of dangerous blood clots than those using older birth-control pills. Full story

Reuters: UPDATE 4-Higher bleeding risk seen in J&J, Bayer clot drug

* Doctors cast doubt on approval for acute illness group Full story

Reuters: REFILE-U.S. employees accuse Bayer of discrimination

(An earlier version quoted Katherine Kimpel saying a weakeconomy lets companies disguise a multitude of things. Thecorrect quote is "multitude of sins.") Full story

U.S. employees accuse Bayer of discrimination

NEW YORK, March 21 (Reuters Legal) - Six former and current employees of a U.S. unit of Bayer AG filed a class-action lawsuit against the company on Monday, alleging gender discrimination in pay, promotions and the treatment of pregnant women and mothers. Full story

Supreme Court won't review drug patent deal

The Supreme Court let stand a ruling that drug companies can pay rivals to delay production of generic drugs without violating federal antitrust laws. Full story

Sponsored Links


Reuters: Bayer issues muted 2011 outlook on generic rivals

Reuters: UPDATE 3-U.S. FDA panel backs Bayer imaging drug

Reuters: UPDATE 1-US FDA weighs skin risks of Bayer imaging drug

Bayer to test drug to treat eye disease in Asia

Bayer expands research work to fight cancer in Asia

Bayer, J&J anti-clot drug shines in stroke trial

Related Photos


Shareholders follow the annual general meeting of German pharmaceutical group Bayer in Cologne, western Germany on April 29, 2011. German chemical giant Bayer revised up its full year forecasts for 2011 on April 28, 2011, pinning its hopes on agrochemistry despite mixed first-quarter results.

Possible Duogynon Victims Attend Bayer Shareholders' Meeting
Possible Duogynon Victims Attend Bayer Shareholders' Meeting

COLOGNE, GERMANY - APRIL 29: Wolf-Dietrich Molzow and Andre Sommer , victims who are convinced their physical handicaps were caused by the pregnancy test drug Duogynon pose with a banner to Bayer shareholders at the Bayer general shareholders??? meeting on April 29, 2011 in Cologne, Germany. The v